Last reviewed · How we verify
NM8074
At a glance
| Generic name | NM8074 |
|---|---|
| Sponsor | NovelMed Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (PHASE2)
- Study of NM8074 in Patients with Dermatomyositis (DM) (PHASE2)
- Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy (PHASE2)
- Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) (PHASE2)
- Study of NM8074 in Adult PNH Patients with Inadequate Response to Soliris (PHASE2)
- Study of NM8074 in Patients with AHUS with Evidence of Ongoing Thrombotic Microangiopathy (PHASE2)
- Study of NM8074 in Adult C3 Glomerulopathy Patients (PHASE1, PHASE2)
- Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NM8074 CI brief — competitive landscape report
- NM8074 updates RSS · CI watch RSS
- NovelMed Therapeutics portfolio CI